首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   967949篇
  免费   71060篇
  国内免费   3969篇
耳鼻咽喉   13150篇
儿科学   24836篇
妇产科学   23769篇
基础医学   137474篇
口腔科学   28901篇
临床医学   85195篇
内科学   189256篇
皮肤病学   19558篇
神经病学   74386篇
特种医学   38053篇
外国民族医学   102篇
外科学   156133篇
综合类   23811篇
现状与发展   13篇
一般理论   237篇
预防医学   63945篇
眼科学   22252篇
药学   76409篇
  18篇
中国医学   4049篇
肿瘤学   61431篇
  2021年   7247篇
  2018年   10214篇
  2017年   8187篇
  2016年   8868篇
  2015年   10582篇
  2014年   14015篇
  2013年   19273篇
  2012年   26902篇
  2011年   27986篇
  2010年   16612篇
  2009年   15706篇
  2008年   26613篇
  2007年   27717篇
  2006年   28338篇
  2005年   27368篇
  2004年   25877篇
  2003年   24872篇
  2002年   24195篇
  2001年   55518篇
  2000年   57468篇
  1999年   47946篇
  1998年   11358篇
  1997年   10133篇
  1996年   10082篇
  1995年   9394篇
  1994年   8709篇
  1993年   7882篇
  1992年   35776篇
  1991年   34215篇
  1990年   32992篇
  1989年   32101篇
  1988年   29190篇
  1987年   28439篇
  1986年   26444篇
  1985年   25255篇
  1984年   17915篇
  1983年   15213篇
  1982年   7823篇
  1979年   15811篇
  1978年   10618篇
  1977年   9069篇
  1976年   7888篇
  1975年   8636篇
  1974年   10472篇
  1973年   9866篇
  1972年   9359篇
  1971年   8857篇
  1970年   8428篇
  1969年   7926篇
  1968年   7202篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
51.
52.
53.
Background Immune checkpoint blockers (ICBs) activate CD8+ T cells, eliciting both anti-cancer activity and immune-related adverse events (irAEs). The relationship of irAEs with baseline parameters and clinical outcome is unclear.Methods Retrospective evaluation of irAEs on survival was performed across primary (N = 144) and secondary (N = 211) independent cohorts of patients with metastatic melanoma receiving single agent (pembrolizumab/nivolumab—sICB) or combination (nivolumab and ipilimumab—cICB) checkpoint blockade. RNA from pre-treatment and post-treatment CD8+ T cells was sequenced and differential gene expression according to irAE development assessed.Results 58.3% of patients developed early irAEs and this was associated with longer progression-free (PFS) and overall survival (OS) across both cohorts (log-rank test, OS: P < 0.0001). Median survival for patients without irAEs was 16.6 months (95% CI: 10.9–33.4) versus not-reached (P = 2.8 × 10−6). Pre-treatment monocyte and neutrophil counts, but not BMI, were additional predictors of clinical outcome. Differential expression of numerous gene pathway members was observed in CD8+ T cells according to irAE development, and patients not developing irAEs demonstrating upregulated CXCR1 pre- and post-treatment.Conclusions Early irAE development post-ICB is associated with favourable survival in MM. Development of irAEs is coupled to expression of numerous gene pathways, suggesting irAE development in-part reflects baseline immune activation.Subject terms: Immunotherapy, Melanoma  相似文献   
54.
55.
56.
57.
PurposeOur purpose was to determine the effect of chemoradiotherapy (CRT) on patient-reported quality of life (QOL) for patients with intact pancreas cancer.Methods and MaterialsWe reviewed a prospective QOL registry for patients with intact, clinically localized pancreatic ductal adenocarcinoma treated with CRT between June 2015 and November 2018. QOL was assessed pre-CRT (immediately before CRT, after neoadjuvant chemotherapy) and at the completion of CRT with the Functional Assessment of Cancer Therapy-Hepatobiliary (FACT-Hep) and its component parts: FACT-General (FACT-G) and hepatobiliary cancer subscore (HCS). A minimally important difference from pre-CRT was defined as ≥ 6, 5, and 8 points for FACT-G, HCS, and FACT-Hep, respectively.ResultsOf 157 patients who underwent CRT, 100 completed both pre- and post-CRT surveys and were included in the primary analysis. Median age at diagnosis was 65 years (range, 23-90). National Comprehensive Cancer Network resectability status was resectable (3%), borderline resectable (40%), or locally advanced (57%). Folinic acid, 5-fluorouracil, irinotecan, and oxaliplatin (FOLFIRINOX) (75%) or gemcitabine and nab-paclitaxel (42%) were given for a median of 6 cycles (range, 0-42) before CRT. Radiation therapy techniques included 3-dimensional conformal (22%), intensity modulated photon (55%), and intensity modulated proton (23%) radiation therapy to a median dose of 50 Gy (range, 36-62.5). Concurrent chemotherapy was most commonly capecitabine (82%). Sixty-three patients (63%) had surgery after CRT. The mean decline in FACT-G, HCS subscale, and FACT-Hep from pre- to post-CRT was 3.5 (standard deviation [SD], 13.7), 1.7 (SD 7.8), and 5.2 (SD 19.4), respectively. Each of these changes were statistically significant, but did not meet the minimally important difference threshold. Pancreatic head tumor location was associated with decline in FACT-Hep. Nausea was the toxicity with the greatest increase from pre- to post-CRT by both physician-assessment and patient-reported QOL.ConclusionsFor patients with intact pancreatic adenocarcinoma, modern CRT is well tolerated with minimal decline in QOL during treatment.  相似文献   
58.
59.
60.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号